News Quantified

PDSB – pds biotechnology corporation (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.

PDS Biotechnology Co. (NASDAQ: PDSB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

13.3%

BEAT

10.1%

IN-LINE

6.8%

MISS

Cantor Fitzgerald

Cantor Fitzgerald

Form 8-K PDS Biotechnology Corp For: May 08

Form SC 13G/A PDS Biotechnology Corp Filed by: BlackRock Inc.

Form 4 PDS Biotechnology Corp For: May 01 Filed by: Toutain Stephan

Form 3 PDS Biotechnology Corp For: May 01 Filed by: Toutain Stephan

Form 8-K PDS Biotechnology Corp For: May 01

Top News Gainers

5/14 Q1/2019 3/31/2019 EPS 1.470 ZacksConsensus N/A ActVsEst N/A - N/A 41.4%

10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%

2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%

7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%

10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%

11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%

12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%

3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%

9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%

12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%

Top News Decliners

2/11 PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock -25.8%

9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%

12/17 Form S-1 PDS Biotechnology Corp -14.9%

3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%

12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%

2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%

11/14 Form S-8 PDS Biotechnology Corp -12.7%

4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%

11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%

6/4 Form S-8 PDS Biotechnology Corp -8.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day